Dose Adult
Uncomplicated urinary tract infections: 200 mg orally twice daily for 7–14 days.
Complicated urinary tract infections: 400 mg orally twice daily for 10–14 days.
Dose Paeds
Not routinely recommended in children due to risk of cartilage toxicity. Use only if benefits outweigh risks under specialist supervision.
Enoxacin Brands
| Brand | Status | Manufacturer | Strength | Formulation | Availability | Price |
|---|---|---|---|---|---|---|
| Penetrex® | Historical/International | Warner-Lambert | 200 mg | Tablet | Not verified in Kenya | N/A |
| Penetrex® | Historical/International | Warner-Lambert | 400 mg | Tablet | Not verified in Kenya | N/A |
| No currently verified PPB-registered Kenyan Enoxacin brands identified. | ||||||
Combinations
No fixed-dose combinations in routine use. Avoid concurrent administration with antacids, iron, zinc or sucralfate.
| Enoxacin More action | |
|---|---|
| Indications | Susceptible urinary tract infections, prostatitis and uncomplicated gonococcal infections where appropriate susceptibility exists. |
| Precautions | Renal impairment, seizure disorders, QT prolongation risk, tendon disorders, elderly patients and adequate hydration. |
| Contraindications | Hypersensitivity to quinolones, pregnancy, breastfeeding and routine use in children/adolescents. |
| Pregnancy/Lactation | Avoid during pregnancy and lactation unless no safer alternative is available. |
| Adverse reaction | Nausea, diarrhoea, headache, dizziness, insomnia, photosensitivity, tendinitis, tendon rupture, QT prolongation and hypersensitivity reactions. |
| Polypharmacy | Interacts with theophylline, warfarin, NSAIDs, antacids, iron, zinc, sucralfate and other QT-prolonging medicines. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Fluoroquinolone Antibiotics |